Squarepoint
IBIO icon

Squarepoint’s iBio IBIO Stock Holding History

Squarepoint’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$873K Buy
+498,872
New +$892K ﹤0.01% 3007
2022
Q1 		– Sell
-178
Closed -$49K – 3152
2021
Q4 		$49K Sell
178
-530
-75% -$202K ﹤0.01% 3023
2021
Q3 		$375K Sell
708
-260
-27% -$162K ﹤0.01% 2134
2021
Q2 		$731K Buy
+968
New +$706K ﹤0.01% 1852
2020
Q3 		– Sell
-37
Closed -$42K – 2643
2020
Q2 		$42K Buy
+37
New +$24.2K ﹤0.01% 2112

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Squarepoint's IBIO Position: Q2 2026 in Review

Squarepoint opened a new position in iBio (IBIO) in Q2 2026: 498,872 shares worth $873K. The stake represents ﹤0.01% of the portfolio and ranks #3007 among its holdings. This is a return to the name: Squarepoint previously reported a position in IBIO as recently as Q4 2021.

Squarepoint first reported a position in IBIO in Q2 2020 and has held it in 5 quarters since. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Squarepoint held 498,872 shares of iBio worth $873K as of Q2 2026.
  • iBio was a new Squarepoint position in Q2 2026.
  • iBio made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3007 holding.
  • Squarepoint first reported a position in iBio in Q2 2020 and has held it in 5 quarters since.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.